FOLD beat EPS expectations by 1670.00%
Feb 23, 2026, 11:34 PM
0.00%
What does FOLD do
Amicus Therapeutics, a Philadelphia-based biotechnology company with 517 employees, went public in 2007 and markets Galafold for Fabry disease and Pombiliti + Opfolda for late-onset Pompe disease. Galafold stabilizes alpha-Gal A enzyme, while Pombiliti + Opfolda enhances enzyme uptake in relevant tissues.
Amicus Therapeutics (FOLD) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Amicus Therapeutics's actual EPS was $0.01, beating the estimate of $0.09 per share, resulting in a 1670.00% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.